Challenges for drug discovery and development in China
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractIntroduction: The drug development industry is restructuring worldwide in terms of the research and development process. As with pharmaceuticals in the west, China faces major challenges for drug discovery and development.

Areas covered: In this review, the authors discuss anti-cancer, anti-allergy, anti-infectious, and proprietary Chinese Medicines (pCM) for various chronic diseases (such as the allergic diseases: eczema, asthma and allergic rhinitis), which remain the contemporary therapeutic strategies that are being explored and developed. Drug transporters, disease specific biomarkers, pharmacophores, bioactive natural products and pharmacogenetics are some aspects of research technologies. Proprietary Chinese medicine remains one of the most popular strategies. There is however the issue of good research documentation of efficacy versus adverse effects. China has a complex healthcare system involving a large patient pool.

Expert opinion: Various factors can impact drug development in China including the concurrent use of both western and Chinese medicines, pharmacogenetic variances, lack of multidisciplinary team impact on disease management and drug safety. China may adopt the current development of big data analysis in other countries such as UK and US to build and centralize a nationwide database for better monitoring and clinical evaluation to provide more efficient care at a lower cost.
All Author(s) ListKam Lun Hon, Vivian W.Y Lee
Journal nameExpert Opinion on Drug Discovery
Volume Number12
Issue Number1
PublisherTaylor & Francis Online
Pages105 - 113
LanguagesEnglish-United Kingdom
KeywordsChallenges, drug discovery and development, China, Chinese medicine, drug transporters, disease specific biomarkers, pharmacophores, bioactive natural products

Last updated on 2020-28-11 at 01:46